ASTRAZENECA, now referred to as Vaxzevria by the Medicines and Healthcare Regulatory Agency (MHRA), has been associated with cases of transverse myelitis – i.e. inflammation of the spinal cord.
As of Wednesday, January 26, transverse myelitis has officially been added to the “warnings and precautions [of] neurological events” section given to healthcare professionals. The MHRA has assured that cases are “extremely rare” but the reaction can lead to: muscle weakness, localised or radiating back pain, and bladder issues. Furthermore, transverse myelitis can lead to bowel symptoms and changes in sensations.